Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

5.9%

1 terminated out of 17 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

24%

4 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed with results

Key Signals

1 with results86% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (2)
P 1 (2)
P 2 (8)
P 3 (4)

Trial Status

Completed6
Active Not Recruiting3
Recruiting3
Not Yet Recruiting2
Unknown2
Terminated1

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT07558668Phase 1RecruitingPrimary

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

NCT05549947Phase 2CompletedPrimary

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

NCT06136741Phase 2Active Not RecruitingPrimary

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT07465120Phase 2Not Yet RecruitingPrimary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT06012812Phase 2CompletedPrimary

A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT07370909Phase 3Not Yet RecruitingPrimary

Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis

NCT06468956Phase 3Active Not RecruitingPrimary

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

NCT06239311Phase 3RecruitingPrimary

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

NCT06099704Active Not RecruitingPrimary

Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis

NCT06723080Phase 3RecruitingPrimary

Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT05997927Phase 2CompletedPrimary

Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT05702268Phase 2UnknownPrimary

Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis

NCT03568162Phase 2CompletedPrimary

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

NCT05197023Phase 1UnknownPrimary

A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

NCT01286220Not ApplicableTerminatedPrimary

Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis

NCT02426359Phase 2CompletedPrimary

Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients

NCT00148746Not ApplicableCompletedPrimary

Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis

Showing all 17 trials

Research Network

Activity Timeline